Aducanumab Opinion
Main Article Content
Abstract
Aducanumab (brand name Aduhelm) is the first FDA-approved, pharmacologic treatment for Alzheimer’s disease (AD) but many uncertainties remain regarding both efficacy and safety. Of paramount concern are associated adverse effects including cerebral edema and hemorrhage which prompted a post-approval study. Aside from safety concerns, withdrawal from the market may occur if it fails to demonstrate efficacy as described in pre-approval reports.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Alexander, G. C., Knopman, D. S., Emerson, S. S., Ovbiagele, B., Kryscio, R. J.,
II. Aducanumab: Drug Information. Uptodate.com. Accessed 7/24/2022.
III. Nania, R. (2021, July 15). FDA approves Aducanumab to treat Alzheimer’s disease. AARP. https://www.aarp.org/health/brain-health/info-2021/fda-biogen-alzheimers-drug.html
IV. Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021). Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer's Research & Therapy, 13(1), 1-3. https://doi.org/10.1186/s13195-021-00838-z
V. Dunn, B., Stein, P., Temple, R., & Cavazzoni, P. (2021). Appropriate use of accelerated approval — Aducanumab for Alzheimer’s disease. New England Journal of Medicine, (2021), 1. https://doi.org/10.1056/nejmc2111960
VI. Salloway, S. (2021, June 11). After the FDA’s approval, what to know about the new Alzheimer’s drug. Brown University. https://www.brown.edu/news/2021-06-11/aducanumab